Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angioguard Inc.

This article was originally published in Start Up

Executive Summary

Devices to catch and contain emboli could improve the outcomes of interventional cardiology procedures..

You may also be interested in...



Embolic Protection: Working the Guidewire With a Net

At this year's Paris Course on Revascularization (PCR), the leading European interventional meeting, embolic protection devices (EPDs) were among the prime subjects, in terms of clinical presentations and company exhibits. Some industry executives had predicted that Medtronic's acquisition last fall of PercuSurge would end the competitive race in this market before it really began. But judging by both the newer companies at the PCR and other recent entrants into this space, it appears that the battle has just begun. There are around 14 companies now competing in this space, six of which have received CE mark. Since none of these companies is on the US market, the initial competitive battle will be fought in Europe. Each of the major cardiology companies has already gotten into this area, generally through acquisitions. But there are also several start-ups that have come up with new technological approaches that are receiving favorable initial clinical reviews, so the debate remains open as to which of three approaches--occlusion balloons, filters, or proximal occlusion/reverse flow systems will ultimately prevail.

The Sell/Go Public Dilemma for Device Companies

With device company investors worried about exit strategies, companies and their financiers are looking for creative ways to get deals done. Limited exit opportunities are making financiers anxious, driving them to put more money into fewer start-ups, which target devices aimed at larger markets. Some entrepreneurs are forming incubators to focus on niche products in which they develop new technologies, then sell them without building companies around them.

Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel